BSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Boston Scientific Corp (BSX) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock has experienced significant price declines year-to-date, and while analysts maintain a generally optimistic outlook with a median price target of $65-$78, the company's lowered growth expectations and bearish technical indicators suggest caution. Additionally, insider selling has surged, and there are no strong proprietary trading signals to support immediate action. Congress trading data shows some positive sentiment, but it is not sufficient to outweigh the current negative catalysts.
The stock is displaying bearish technical indicators. The MACD is negative and expanding, RSI is neutral at 21.357, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level (S1: 45.101), with resistance levels at R1: 49.456 and R2: 50.802. This suggests limited upward momentum in the short term.
Congress trading data shows a positive attitude with 6 purchase transactions totaling $2.0M to $12.5M.
Analysts maintain a Buy rating with a median price target of $65-$78, indicating potential upside in the long term.
Insider selling has surged by 755.62% in the last month.
The company has lowered its growth expectations for 2026 and 2027, particularly for its Watchman franchise.
Bearish technical indicators and a year-to-date price decline of over 50%.
No proprietary trading signals (AI Stock Picker or SwingMax) to support immediate action.
No financial data available for the latest quarter, but management has revised 2026 revenue growth forecasts down to 6.5%-8%. Analysts expect slower growth for the Watchman franchise in Q2 and Q3, with a gradual recovery in 2027.
Analysts maintain a generally optimistic outlook with Buy ratings from major firms like Piper Sandler, BofA, Truist, and Goldman Sachs. However, price targets have been lowered across the board due to reduced growth expectations and valuation concerns. Wolfe Research downgraded the stock to Peer Perform, citing limited upside potential in the near term.
